Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, January 10th. The stock was sold at an average price of $22.86, for a total value of $228,600.00. Following the completion of the transaction, the insider now directly owns 1,250,148 shares in the company, valued at $28,578,383.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Day One Biopharmaceuticals Stock Up 0.7 %
Shares of DAWN stock opened at $22.98 on Thursday. The stock's fifty day simple moving average is $20.80 and its 200 day simple moving average is $20.83. Day One Biopharmaceuticals, Inc. has a one year low of $5.44 and a one year high of $28.35.
Get Day One Biopharmaceuticals alerts:Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) last posted its quarterly earnings data on Monday, November 7th. The company reported ($0.53) EPS for the quarter, hitting analysts' consensus estimates of ($0.53). Equities research analysts expect that Day One Biopharmaceuticals, Inc. will post -2.18 EPS for the current fiscal year.
Hedge Funds Weigh In On Day One Biopharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Atlas Venture Life Science Advisors LLC boosted its stake in Day One Biopharmaceuticals by 9.3% in the second quarter. Atlas Venture Life Science Advisors LLC now owns 8,968,305 shares of the company's stock worth $160,533,000 after purchasing an additional 766,667 shares in the last quarter. FMR LLC boosted its stake in Day One Biopharmaceuticals by 163.1% in the second quarter. FMR LLC now owns 6,826,574 shares of the company's stock worth $122,196,000 after purchasing an additional 4,232,055 shares in the last quarter. RA Capital Management L.P. boosted its stake in Day One Biopharmaceuticals by 22.0% in the first quarter. RA Capital Management L.P. now owns 6,060,090 shares of the company's stock worth $60,116,000 after purchasing an additional 1,094,502 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its stake in Day One Biopharmaceuticals by 68.3% in the second quarter. Deerfield Management Company L.P. Series C now owns 3,512,123 shares of the company's stock worth $62,867,000 after purchasing an additional 1,425,674 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in Day One Biopharmaceuticals by 29.5% in the third quarter. BlackRock Inc. now owns 2,541,235 shares of the company's stock worth $50,901,000 after purchasing an additional 578,511 shares in the last quarter. Institutional investors and hedge funds own 86.08% of the company's stock.Wall Street Analyst Weigh In
DAWN has been the topic of a number of research reports. Piper Sandler boosted their price objective on Day One Biopharmaceuticals from $40.00 to $45.00 and gave the company an "overweight" rating in a research report on Sunday. Bank of America initiated coverage on Day One Biopharmaceuticals in a research report on Thursday, December 1st. They set a "buy" rating and a $34.00 price objective on the stock. Needham & Company LLC initiated coverage on Day One Biopharmaceuticals in a research report on Wednesday, December 14th. They set a "buy" rating and a $40.00 price objective on the stock. HC Wainwright boosted their price objective on Day One Biopharmaceuticals from $35.00 to $45.00 and gave the company a "buy" rating in a research report on Monday. Finally, The Goldman Sachs Group boosted their price objective on Day One Biopharmaceuticals from $45.00 to $62.00 and gave the company a "buy" rating in a research report on Monday. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of "Buy" and an average target price of $43.50.
About Day One Biopharmaceuticals
(Get Rating)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
Featured Articles
- Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.